Clearmind Medicine (CMND) has received Institutional Review Board approval from Tel Aviv Sourasky Medical Center in Tel Aviv, Israel, for its ongoing Phase 1/2a clinical trial evaluating CMND-100, a proprietary MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder. This approval will enable patient enrollment at TASMC prior to commencing this first-in-human trial at the site. The trial includes other institutions, such as Yale School of Medicine’s Department of Psychiatry, Johns Hopkins University School of Medicine and Hadassah-University Medical Center in Jerusalem, Israel. The study at TASMC will be led by Dr. David Zeltser, Director of the Emergency Medicine Department and Deputy Director R&D and Innovation. Clearmind recently announced the dosing of the first participant in the trial, marking a historic step toward developing a novel therapy for the millions affected by AUD worldwide.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMND:
- Clearmind Medicine announces first participant ever dosed with CMND-100
- Clearmind Medicine expands global clinical trial targeting AUD market
- Psychedelic: Compass Pathways achieves primary endpoint in COMP360 trial
- Clearmind Medicine enrolls first patient in Phase I/IIa trial for CMND-100
- Mike Davis to become CDER deputy director, Pink Sheet’s Gingery says